Muromonab-CD3 therapy for refractory rejections after liver transplantation: A single-center experience during two decades in Japan

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 17, Issue 6, 2010, Pages 885-891

  Ueda, Daisuke ^a   Hori, Tomohide ^a,b   Nguyen, Justin H ^b   Uemoto, Shinji ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

^b MAYO CLINIC   (United States)

Author keywords

Liver transplantation; Muromonab CD3; OKT3; Retransplantation; Steroid resistant rejection

Indexed keywords

CD3 ANTIGEN; CHLORPHENIRAMINE MALEATE; HYDROCORTISONE; METHYLPREDNISOLONE; OKT 3; PREDNISOLONE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; END STAGE LIVER DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; JAPAN; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PNEUMONIA; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; SEPSIS; TREATMENT DURATION; ADOLESCENT; CHILD; COMPARATIVE STUDY; DOSE RESPONSE; FLOW CYTOMETRY; FOLLOW UP; GRAFT REJECTION; INCIDENCE; INFANT; LIVER DISEASE; MIDDLE AGED; NEEDLE BIOPSY; PRESCHOOL CHILD; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOPSY, NEEDLE; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; JAPAN; LIVER DISEASES; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MUROMONAB-CD3; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952198334     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-010-0288-y     Document Type: Article

References (29)

1. Egawa H, Ohdan H, Haga H, Tsuruyama T, Oike F, Uemoto S, et al. Current status of liver transplantation across ABO blood-type barrier. J Hepatobiliary Pancreat Surg. 2008;15:131-8. (Pubitemid 351516970)
2. Yoshizawa A, Sakamoto S, Ogawa K, Kasahara M, Uryuhara K, Oike F, et al. New protocol of immunosuppression for liver transplantation across ABO barrier: the use of Rituximab, hepatic arterial infusion, and preservation of spleen. Transplant Proc. 2005;37:1718-9.
3. Ueda M, Oike F, Ogura Y, Uryuhara K, Fujimoto Y, Kasahara M, et al. Long-term outcomes of 600 living donor liver transplants for pediatric patients at a single center. Liver Transpl. 2006;12:1326-36. (Pubitemid 44405121)
4. Ogura Y, Kaihara S, Haga H, Kozaki K, Ueda M, Oike F, et al. Outcomes for pediatric liver retransplantation from living donors. Transplantation. 2003;76:943-8. (Pubitemid 37186024)
5. Martin SR, Atkison P, Anand R, Lindblad AS. Studies of Pediatric Liver Transplantation 2002: patient and graft survival and rejection in pediatric recipients of a first liver transplant in the United States and Canada. Pediatr Transplant. 2004;8:273-83.
6. Margarit C, Rimola A, Gonzalez-Pinto I, Cuervas-Mons V, Edo A, Andreu H, et al. Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. Transpl Int. 1998;11(Suppl 1):S260-6.
7. Sakamoto S, Haga H, Egawa H, Kasahara M, Ogawa K, Takada Y, et al. Living donor liver transplantation for acute liver failure in infants: the impact of unknown etiology. Pediatr Transplant. 2008;12:167-73. (Pubitemid 351326913)
8. Alonso EM, Piper JB, Echols G, Thistlethwaite JR, Whitington PF. Allograft rejection in pediatric recipients of living related liver transplants. Hepatology. 1996;23:40-3. (Pubitemid 26012089)
9. Joseph JT, Kingsmore DB, Junor BJ, Briggs JD, Mun Woo Y, Jaques BC, et al. The impact of late acute rejection after cadaveric kidney transplantation. Clin Transplant. 2001;15:221-7. (Pubitemid 32725403)
10. Blakolmer K, Jain A, Ruppert K, Gray E, Duquesnoy R, Murase N, et al. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation. 2000;69:2330-6. (Pubitemid 30408998)
11. Blakolmer K, Seaberg EC, Batts K, Ferrell L, Markin R, Wiesner R, et al. Analysis of the reversibility of chronic liver allograft rejection implications for a staging schema. Am J Surg Pathol. 1999;23:1328-39. (Pubitemid 29517326)
12. Hooks MA, Wade CS, Millikan WJ Jr. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy. 1991;11:26-37.
13. Hori T, Egawa H, Takada Y, Oike F, Ogura Y, Ogawa K, et al. Fatal impact of lymphocyte cross-matching upon humoral rejection after adult living related liver transplantation. Transpl Int. 2010;23:338-340
14. Mazariegos GV, Salzedas AA, Zavatsky J, Sindhi R, Parizhskaya M, McGhee W, et al. Long term management of liver transplant rejection in children. BioDrugs. 2000;14:31-48. (Pubitemid 30643209)
15. Solomon H, Gonwa TA, Mor E, Holman MJ, Gibbs J, Watemberg I, et al. OKT3 rescue for steroid-resistant rejection in adult liver transplantation. Transplantation. 1993;55:87-91. (Pubitemid 23033951)
16. Goldstein G, Kremer AB, Barnes L, Hirsch RL. OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients. J Pediatr. 1987;111:1046-50. (Pubitemid 18024935)
17. Todd PA, Brogden RN. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs. 1989;37:871-99.
18. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology. 1997;25:658-63.
19. Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology. 2000;31:792-9.
20. Neil DA, Hubscher SG. Histologic and biochemical changes during the evolution of chronic rejection of liver allografts. Hepatology. 2002;35:639-51. (Pubitemid 34183970)
21. Austin GL, Sasaki AW, Zaman A, Rabkin JM, Olyaei A, Ruimy R, et al. Comparative analysis of outcome following liver transplantation in US veterans. Am J Transplant. 2004;4:788-95. (Pubitemid 38637579)
22. Habib S, Berk B, Chang CC, Demetris AJ, Fontes P, Dvorchik I, et al. MELD and prediction of post-liver transplantation survival. Liver Transpl. 2006;12:440-7.
23. Gayowski T, Marino IR, Singh N, Doyle H, Wagener M, Fung JJ, et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation. 1998;65:499-504.
24. Oguma S, Belle S, Starzl TE, Demetris AJ. A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischemic factors. Hepatology. 1989;9:204-9. (Pubitemid 19063302)
25. Gupta P, Kaufman S, Fishbein TM. Sirolimus for solid organ transplantation in children. Pediatr Transplant. 2005;9:269-76. (Pubitemid 40780355)
26. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993;342:1514-6. (Pubitemid 23362168)
27. Kimball JA, Norman DJ, Shield CF, Schroeder TJ, Lisi P, Garovoy M, et al. The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation. Transpl Immunol. 1995;3:212-21.
28. Caballero A, Fernandez N, Lavado R, Bravo MJ, Miranda JM, Alonso A. Tolerogenic response: allorecognition pathways. Transpl Immunol. 2006;17:3-6. (Pubitemid 44828808)
29. Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Transpl Immunol. 2002;10:101-8.